glp-1 lawsuits news ad war leads to lawsuit by Novo Nordisk, claiming Eli Lilly misleads Alarming rise in weight loss

February 2026 a signaled reversal

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

When studies reported multiple brain regions or several blood components (plasma, serum, blood cells), each region or component was extracted as a sub-study

Patients who used Zepbound for 36 weeks lost an average of 21%, but then, when switched to a placebo, after 1 year, they had regained 14% of their weight back

Their ability to fight inflammation also benefits brain and liver health

BPC-157 fits perfectly in cutting-edge HRT and peptide therapy packages